Literature DB >> 9363934

IL-5 as a strong secretagogue for human eosinophils.

T Fujisawa1, A Terada, J Atsuta, K Iguchi, H Kamiya, M Sakurai.   

Abstract

The ability of IL-5 to induce eosinophil degranulation was investigated. Peripheral blood eosinophils from patients with mildly allergic individuals were isolated with CD16- selection method. Eosinophils were then incubated with interleukin-5 (IL-5) (0.1-100 ng/ml) for 1-48 h and EPX in the supernatants were measured with RIA. We found that IL-5 induced significant amount of eosinophil protein X in a concentration-dependent manner at 24 h. Eosinophil viability was about 90% either in the presence or absence of IL-5 at 24 h. Eosinophils stimulated with IL-5 adhered to the plate. Anti-CD18 mAb blocked adhesion and degranulation induced by IL-5. Dexamethasone and TGFbeta significantly inhibited degranulation in a concentration-dependent manner. These results suggest that IL-5 may be a strong secretagogue for eosinophils, that adhesion via beta2 integrin is a requisite for degranulation, and that the anti-inflammatory effect of corticosteroids and TGFbeta may be exerted at least in part, through the inhibition of eosinophil degranulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9363934     DOI: 10.1159/000237726

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  3 in total

1.  Degranulating eosinophils in human endometriosis.

Authors:  R D Blumenthal; M Samoszuk; A P Taylor; G Brown; R Alisauskas; D M Goldenberg
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Perturbations in eosinophil homeostasis following treatment of lymphatic filariasis.

Authors:  R Gopinath; L E Hanna; V Kumaraswami; V Perumal; V Kavitha; V Vijayasekaran; T B Nutman
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

3.  Distribution of major basic protein on human airway following in vitro eosinophil incubation.

Authors:  Ailing Xue; John Wang; Gary C Sieck; Mark E Wylam
Journal:  Mediators Inflamm       Date:  2010-03-22       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.